IAV H2 Subtype HA Specific Neutra™ Antibody Products

Are you currently facing the looming threat of pandemic reassortment or the technical hurdles of developing broad-spectrum antivirals? Our IAV H2 Subtype HA Specific Neutra™ Antibody Products help you develop highly specific countermeasures and streamline pandemic preparedness through advanced recombinant DNA technology and high-precision epitope-targeted screening platforms. Creative Biolabs is dedicated to providing premium reagents that ensure your research stays ahead of emerging viral threats.

Introduction of IAV H2 Subtype HA

Influenza A Virus (IAV) is categorized into subtypes based on the antigenic properties of its surface glycoproteins: Hemagglutinin (HA) and Neuraminidase (NA). Among these, the H2 subtype gained global notoriety during the 1957 "Asian Flu" pandemic (H2N2), which resulted in an estimated 1.1 million deaths worldwide. Although H2N2 ceased circulating in humans in 1968, it persists in avian reservoirs, presenting a persistent risk of re-emergence through antigenic shift.

Structure and Function of H2 Hemagglutinin

The H2 HA protein is a homotrimeric integral membrane glycoprotein. Each monomer is synthesized as a precursor (HA0) that must be cleaved by host proteases into two subunits, HA1 and HA2, to become infectious.

• HA1 Subunit: Forms the globular head and contains the Receptor Binding Site (RBS), which specifically recognizes α-2,3-linked or α-2,6-linked sialic acids on host cells.
• HA2 Subunit: Forms the stalk or stem domain, housing the fusion peptide. This region is highly conserved across various influenza strains and is critical for the pH-dependent membrane fusion process that occurs within the endosome.

Fig.1 Structure of the influenza HA protein.¹

Clinical Impact and Signaling

Upon infection, HA mediates viral attachment and internalization via receptor-mediated endocytosis. The acidic environment of the endosome (pH 5.0–5.5) triggers an irreversible conformational change in the HA trimer, exposing the fusion peptide to facilitate the release of the viral ribonucleoprotein (vRNP) complex into the host cytoplasm. Acidification in endosomes induces HA conformational changes, activating MAPK/ERK and PI3K/Akt pathways. These signals facilitate viral ribonucleoprotein (vRNP) nuclear import and suppress early apoptotic responses.

Given that individuals born after 1968 lack natural immunity to H2 subtypes, the development of neutralizing antibodies is a top priority for global health security.

Applications of anti IAV H2 Subtype HA Neutralizing Antibodies

Neutralizing antibodies (nAbs) against the H2 subtype are indispensable in both clinical and basic research settings:

• Passive Immunotherapy: Passive administration of anti-H2 nAbs can provide immediate protection in post-exposure scenarios or for immunocompromised patients during an outbreak.
• Vaccine Design and Characterization: Researchers use these antibodies to identify and stabilize "universal" epitopes in the HA stem, aiding the design of chimeric HA immunogens that elicit broad protection.
• Viral Entry Assays: By blocking specific stages of the viral life cycle, either receptor binding (head-targeting) or membrane fusion (stem-targeting), these antibodies serve as precise probes to study viral mechanics.
• Diagnostic Surveillance: Anti-H2 nAbs are used in Hemagglutination Inhibition (HI) and Microneutralization (MN) assays to monitor zoonotic shifts in avian populations and evaluate the efficacy of experimental vaccines.

Our Anti-IAV H2 Subtype HA Specific Neutra™ Antibody Products

Creative Biolabs offers a specialized portfolio of Neutra™ antibodies tailored for the H2 subtype, ensuring high-performance results for your laboratory:

• Stem-Directed Broadly Neutralizing Antibodies: Designed to target the conserved hydrophobic groove of the HA2 subunit. These antibodies prevent the "loop-to-helix" transition required for membrane fusion, offering potential cross-reactivity with other Group 1 influenza viruses.
• RBS-Specific Monoclonal Antibodies: High-affinity IgG molecules that sterically hinder the interaction between the HA globular head and host sialic acid receptors, effectively preventing viral attachment.
• Recombinant Human & Chimeric Formats: To minimize immunogenicity in translational studies, we provide antibodies in humanized formats, expressed in advanced mammalian systems to ensure proper glycosylation and folding.
• High-Throughput Screening Support: Our antibodies are validated for use in automated platforms, providing reproducible data for large-scale antiviral compound screening.

Each lot undergoes rigorous QC, including affinity kinetics and virus-neutralization titer verification.

Creative Biolabs is at the forefront of influenza research, providing the scientific community with high-titer, high-specificity IAV H2 Subtype HA Specific Neutra™ Antibody Products. Whether you are working on the next generation of universal flu vaccines or investigating viral pathogenesis, our products deliver the precision and reliability your project demands.

Contact Our Team for More Information and to Discuss Your Project.

Reference

1. Han, Lifen et al. "Structural Insights for Anti-Influenza Vaccine Design." Computational and structural biotechnology journal vol. 17 475-483. 23 Mar. 2019, Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1016/j.csbj.2019.03.009